Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00461097
Other study ID # DAIT CoFAR3
Secondary ID COFARU19AI066738
Status Completed
Phase Phase 2
First received April 16, 2007
Last updated November 15, 2017
Start date May 2007
Est. completion date December 2013

Study information

Verified date November 2017
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.


Description:

In the United States, as many as 6% to 8% of children are affected by food allergy. In young children, allergic reactions to egg can range from mild rash to systemic anaphylaxis. The usual standard of care for allergy is complete avoidance of this food allergen and treatment of accidental systemic reactions by access to self-injected epinephrine. However, accidental exposure to allergens in processed foods may be difficult to avoid. Currently, several therapeutic strategies are being investigated to prevent and treat food allergies. Since standard injection (under the skin) immunotherapy for food allergy is associated with a high rate of allergic reactions, a few studies have recently tried oral immunotherapy (OIT) in food allergy. The purpose of this study is to determine the safety and efficacy of the administration of OIT. The intent is to develop desensitization and eventually tolerance to egg allergen. This study will evaluate tolerance to egg white solid that may be gained by gradually increasing the amounts of egg white solid given to a child over a long period of time.

This study will last up to 48 months. The participants will be randomly assigned to receive oral immunotherapy treatment with egg white solid or placebo. This study will include dose escalation and maintenance followed by oral food challenge (OFC).

For participants receiving egg OIT, visit 1 consists of multiple small incremental doses of egg white solid. This is followed by 32-40 weeks of gradual dose escalation to a stable maintenance dose of egg white solid for at least 8 weeks. At approximately Week 44, participants are given an OFC using 5 grams of egg white solid to identify desensitized individuals. Participants and study staff are unblinded following this initial OFC. Maintenance egg OIT therapy is continued for an additional 1-3 years. Oral Food Challenges with 10 grams of egg white solid will be performed for participants on maintenance egg OIT at subsequent time points (approximately Week 96 and annually thereafter) to test for desensitization. If passed, a repeat OFC after being off therapy for 4-6 weeks will be performed to test for tolerance. An OFC to test for tolerance will use 10 grams of egg white solid and be followed by an open feeding of egg.

Participants receiving placebo during dose escalation and maintenance are given an OFC using 5 grams of egg white solid to test for desensitization at approximately 44 weeks. They are unblinded at that time, continue on an egg-restricted diet, and are followed until up to 2 years. These participants will only receive an OFC at a subsequent time point if their egg Immunoglobulin E (IgE) declines to be less than 2 kilounits of antibody per liter; this OFC will use 10 grams of egg white solid and be followed by an open feeding of egg.

At selected visits, blood and urine collection, physical examination, prick skin tests, and atopic dermatitis and asthma evaluations will occur.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date December 2013
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender All
Age group 5 Years to 18 Years
Eligibility Inclusion Criteria:

- Convincing clinical history of egg allergy

- Age 6 to 18 years, with a serum IgE [UniCAP] to egg > 5 kUA/L OR

- Age 5 to 6 years, with a serum IgE [UniCAP] to egg = 12kUA/L

- Parent/guardian willing to provide informed consent

- Willing to use acceptable forms of contraception

Exclusion Criteria:

- History of severe anaphylaxis to egg. More information on this criterion can be found in the protocol.

- Known allergy to corn

- Chronic disease requiring therapy (e.g., heart disease, diabetes). Participants who have asthma, atopic dermatitis, or rhinitis are not excluded.

- Participation in any interventional study for the treatment of food allergy in the 6 months prior to study entry

- Participant is on "build-up phase" of immunotherapy and has not reached maintenance dosing. Participants tolerating maintenance allergen immunotherapy are not excluded.

- Severe asthma, uncontrolled mild or moderate asthma. More information on this criterion can be found in the protocol.

- Inability to discontinue antihistamines for the initial day of escalation, skin testing, and OFC

- Omalizumab or other nontraditional forms of oral or sublingual allergen immunotherapy, immunomodulator therapy, or biologic therapy in the 12 months prior to study entry. Participants who have taken corticosteroids are not excluded.

- Investigational drugs 90 days prior to study entry or planned use of an investigational drug during the study period

- Pregnancy or breastfeeding

Study Design


Intervention

Drug:
Egg oral immunotherapy
Egg white solid powder
Control Group
Placebo for egg white solid

Locations

Country Name City State
United States Johns Hopkins University School of Medicine Baltimore Maryland
United States University of North Carolina Chapel Hills North Carolina
United States National Jewish Medical and Research Center Denver Colorado
United States University of Arkansas Children's Hospital Research Institute Little Rock Arkansas
United States Mount Sinai School of Medicine New York New York

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Consortium of Food Allergy Research

Country where clinical trial is conducted

United States, 

References & Publications (4)

Baral VR, Hourihane JO. Food allergy in children. Postgrad Med J. 2005 Nov;81(961):693-701. Review. — View Citation

Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Stablein D, Henning AK, Vickery BP, Liu AH, Scurlock AM, Shreffler WG, Plaut M, Sampson HA; Consortium of Food Allergy Research (CoFAR). Oral immunotherapy for treatment of egg allergy i — View Citation

Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol. 2006 Feb;117(2 Suppl Mini-Primer):S470-5. Review. — View Citation

Wood RA. The natural history of food allergy. Pediatrics. 2003 Jun;111(6 Pt 3):1631-7. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Participants Who Successfully Consumed 10,000 mg of Egg White Solid Followed by Open Feeding of Egg Tolerance Assessment: Participants who successfully consumed without dose-limiting symptoms 10,000 mg of egg white solid during a double-blind placebo-controlled oral food challenge were then given an open feeding of egg and those who successfully consumed the open feeding of egg were counted as successes. At the 2 year time point; Egg OIT participants must be approximately 4-6 weeks post-discontinuation of therapy
Secondary Percent of Participants Who Successfully Consumed 5,000 mg of Egg White Solid Desensitization assessment: Participants who successfully consumed without dose-limiting symptoms 5,000 mg of egg white solid during a double-blind placebo-controlled oral food challenge were counted as successes. Following the blinded desensitization phase at approximately Week 44
Secondary Percent of Participants Who Successfully Consumed a 50 mg Dose at Initial Escalation On the initial day of dosing, participants were offered 0.1 mg of egg white solid or placebo followed by an approximate doubling every 30 minutes up to a 50 mg dose providing limiting reactions do not occur. Initial day of dosing
Secondary Percent of Participants Who Achieved a Maintenance Dose of 2,000 mg For participants whose maximum tolerated dose on the initial escalation day was less than 50 mg, doses were doubled every 2 weeks up to 50 mg. After 50 mg, dosing was increased to 75 mg, and then dosing increased by 25% until the 2000 mg dose was reached. The maximum time allowed for the build-up phase was 40 weeks; the dose achieved at 40 weeks was considered the maintenance dose. Following the blinded desensitization phase at approximately Week 44
Secondary Number of Participants With Serious Adverse Events (SAEs) This study graded the severity of Adverse Events experienced by participants according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3. Baseline through the 2-year primary endpoint
Secondary Percent of Participants in the Egg OIT Treatment Arm Who Successfully Consumed 10,000 mg of Egg White Solid Tolerance Assessment: Participants in the Egg OIT treatment arm who were not tolerant at 2 years were offered an additional 2 years of therapy. A 10,000 mg double-blind placebo controlled oral food challenge to egg was done the same way as the one performed at 2 years for these participants in order to identify tolerant individuals in the 2 to 4 year extension segment. The tolerant individuals from this segment were then added to the tolerant individuals from the 2 year segment. 4 years (48 months)
See also
  Status Clinical Trial Phase
Completed NCT04531540 - Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test) Phase 3
Completed NCT00988065 - Sugammadex Hypersensitivity Study (Study P06042) Phase 1
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02588326 - Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays Phase 1
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02352168 - Airway Inflammation in Children With Allergic Rhinitis and Intervention N/A
Completed NCT02360072 - Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Completed NCT01494649 - Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity N/A
Enrolling by invitation NCT05039229 - Measures for Bioaerosol Reduction in the Salmon Industry N/A
Enrolling by invitation NCT05675241 - Characterizing the Inflammation Around Dental Implants
Completed NCT04006106 - Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Completed NCT04605471 - A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Terminated NCT05247567 - Quaternary Ammonium and Immunization in Hairdressers N/A
Completed NCT05119751 - Vestibular Versus Sublingual Route of AIT Tablets Phase 4
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Not yet recruiting NCT04485299 - Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient Phase 2/Phase 3
Completed NCT02686827 - DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. Phase 2